EHL BIO Celebrates 10th Anniversary with Relocation of Headquarters and Cell Center to Apgujeong

A Major Step into the Second Decade in Apgujeong

In celebration of a successful decade in regenerative medicine, EHL BIO has relocated its headquarters and EHL Cell Center to the new EHL Building located in the prestigious Apgujeong district of Gangnam, Seoul. This move represents more than just a physical expansion; it symbolizes a renewed commitment to advancing clinical research and providing superior medical services.

Being situated in Gangnam, a global hub for medical excellence, enables EHL BIO to better collaborate within its extensive network of over 100 partner hospitals in South Korea. This strategic positioning directly contributes to enhancing the quality of life for international patients and setting new benchmarks in medical standards.

Advanced Research Center and Cell Culture Technology

The new headquarters and research center are designed to house the most advanced medical technologies. The facility features state-of-the-art GMP (Good Manufacturing Practices) facilities, including Class 100 Clean Rooms, ensuring the highest levels of purity and safety during the cell isolation and cultivation processes.

With a production capacity of 6,000 lots per year, EHL BIO maintains its leadership with robust technology for isolating adipose-derived stem cells, yielding up to 1,000 times more cells than conventional methods. The facility also utilizes cryogenic storage systems at -196°C to preserve cell viability and quality for future clinical applications in regenerative medicine.

Relocating our headquarters and Cell Center to Apgujeong is our 10th-anniversary promise to deliver the best regenerative medicine technology to people worldwide.

Global Readiness and Patient Services

The new location enhances EHL BIO’s capability to serve global patients, supported by EHL Thailand’s dedicated coordination team. The process is streamlined from the initial consultation and specialist medical assessment to travel planning for services at the EHL Building in Apgujeong.

Patients access treatment protocols that meet high safety standards, regulated under South Korea's 'Advanced Regenerative Bio Act.' The comprehensive process includes sample collection at EHL Cell Clinic, cultivation in quality-controlled GMP facilities, and continuous follow-up care after returning home, ensuring a seamless experience for Thai patients.

Future Vision of EHL BIO

Under the leadership of CEO MD Hong-gi Lee, EHL BIO continues to focus on R&D to overcome age-related degenerative conditions and chronic diseases, such as Chronic Kidney Disease (KDSTEM) and Atopic Dermatitis (ADSTEM), which are currently in advanced medical development phases.

Relocating on the 10th anniversary is a pivotal step toward establishing EHL BIO as a leading biotechnology institute dedicated to humanity. By utilizing innovative cell therapies and Exosomes to prolong life expectancy and promote sustainable health, the company integrates advanced medical technology with world-class production standards in its highly efficient new workspace.